ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 274,48
-0,27%
Dow Jones
42 840,26
1,18%
DAX
19 884,75
-0,57%
Brent Oil
72,72
0,00%
Bitcoin
96 234,67
-1,00%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Lucid Diagnostics Inc (LUCD) Cours

Lucid Diagnostics Inc

Lucid Diagnostics Inc (LUCD)

NASDAQ
0,781
0,0101
(1,31%)
Fermé 22 Décembre 10:00PM
Retardé de 15 minutes
0,78
-0,001
(-0,13%)
Après les heures de négociation: 1:31AM
Retardé de 15 minutes

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Statistiques et détails clés

Dernier
0,78
Prix Achat
0,78
Prix Vente
1,50
Volume échangé
366 933
0,78 Fourchette du Jour 0,7999
0,6301 Plage de 52 semaines 1,58
Cap du marché
46,287M
Clôture Veille
0,7709
Ouverture
0,784949
Dernière Transaction
1
@
0.795
Dernière heure de transaction
Volume financier
US$ 289 170
VWAP
0,788074
Volume moyen (3 m)
455 496
Actions en circulation
59 342 479
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-0,88
Bénéfice par action (BPA)
-0,89
Chiffre d'affairess
2,43M
Bénéfice net
-52,67M

À propos de Lucid Diagnostics Inc

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically hig... Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard. Show more

Secteur
Surgical,med Instr,apparatus
Industrie
Surgical,med Instr,apparatus
Siège social
Wilmington, Delaware, USA
Fondé
-
Lucid Diagnostics Inc est coté dans le secteur Surgical,med Instr,apparatus de la NASDAQ avec le ticker LUCD. Le dernier cours de clôture d'Lucid Diagnostics était de US$0,77. Au cours de la dernière année, les actions de Lucid Diagnostics ont été négociées dans une fourchette de prix de US$ 0,6301 à US$ 1,58.

Lucid Diagnostics compte actuellement 59 342 479 actions en circulation. La capitalisation boursière d'Lucid Diagnostics est de US$45,75 million. Lucid Diagnostics a un ratio cours/bénéfice (ratio PE) de -0.88.

LUCD Dernières nouvelles

Plus de nouvelles

Form 8-K - Current report

20 Décembre 2024
Edgar (US Regulatory)

Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters

Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters PR Newswire NEW YORK, Dec. 19, 2024 Partnership launched with fully-contracted...

19 Décembre 2024
PR Newswire (US)

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication PR Newswire NEW YORK, Dec. 11, 2024 Study demonstrates outstanding...

11 Décembre 2024
PR Newswire (US)

Form D - Notice of Exempt Offering of Securities

06 Décembre 2024
Edgar (US Regulatory)

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones PR Newswire NEW YORK, Dec. 3, 2024 New convertible debt...

03 Décembre 2024
PR Newswire (US)

Form 8-K - Current report

29 Novembre 2024
Edgar (US Regulatory)

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test PR Newswire NEW YORK, Nov. 20, 2024 NEW YORK, Nov. 20, 2024 /PRNewswire/...

20 Novembre 2024
PR Newswire (US)

Form 8-K - Current report

18 Novembre 2024
Edgar (US Regulatory)

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum PR Newswire NEW YORK, Nov. 18, 2024 NEW YORK, Nov. 18, 2024 /PRNewswire/...

18 Novembre 2024
PR Newswire (US)

PAVmed Provides Business Update and Third Quarter 2024 Financial Results

PAVmed Provides Business Update and Third Quarter 2024 Financial Results PR Newswire NEW YORK, Nov. 14, 2024 Lucid reports record quarterly EsoGuard® revenue and completes clinical evidence...

14 Novembre 2024
PR Newswire (US)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1000.780.830.76025209210.79560822CS
4-0.2-20.40816326530.981.020.7536258210.87380448CS
12-0.006-0.7633587786260.7861.120.7534554960.91240151CS
260.0913.04347826090.691.120.6813089800.88347638CS
52-0.51-39.53488372091.291.580.63012320940.92230877CS
156-4.15-84.17849898584.935.870.63011430661.67015911CS
260-11.97-93.882352941212.7513.50.63011532092.59052651CS

LUCD - Frequently Asked Questions (FAQ)

What is the current Lucid Diagnostics share price?
The current share price of Lucid Diagnostics is US$ 0,78
How many Lucid Diagnostics shares are in issue?
Lucid Diagnostics has 59 342 479 shares in issue
What is the market cap of Lucid Diagnostics?
The market capitalisation of Lucid Diagnostics is USD 45,75M
What is the 1 year trading range for Lucid Diagnostics share price?
Lucid Diagnostics has traded in the range of US$ 0,6301 to US$ 1,58 during the past year
What is the PE ratio of Lucid Diagnostics?
The price to earnings ratio of Lucid Diagnostics is -0,88
What is the cash to sales ratio of Lucid Diagnostics?
The cash to sales ratio of Lucid Diagnostics is 19,07
What is the reporting currency for Lucid Diagnostics?
Lucid Diagnostics reports financial results in USD
What is the latest annual turnover for Lucid Diagnostics?
The latest annual turnover of Lucid Diagnostics is USD 2,43M
What is the latest annual profit for Lucid Diagnostics?
The latest annual profit of Lucid Diagnostics is USD -52,67M
What is the registered address of Lucid Diagnostics?
The registered address for Lucid Diagnostics is CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
Which industry sector does Lucid Diagnostics operate in?
Lucid Diagnostics operates in the SURGICAL,MED INSTR,APPARATUS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
MYSZMy Size Inc
US$ 4,2001
(211,12%)
121,03M
NVNINVNI Group Ltd
US$ 8,26
(209,36%)
78,06M
TPICTPI Composites Inc
US$ 2,45
(100,82%)
34M
ICGIntchains Group Ltd
US$ 8,77
(88,60%)
527,94k
HSDTHelius Medical Technologies Inc
US$ 0,884851
(84,34%)
121,95M
CYNCYNGN Inc
US$ 0,4603
(-71,41%)
27,5M
MTEMMolecular Templates Inc
US$ 0,1502
(-57,09%)
8,63M
PRFXPainReform Ltd
US$ 5,15
(-53,85%)
2,84M
GALTGalectin Therapeutics Inc
US$ 1,03
(-48,50%)
8,58M
BCABBioAtla Inc
US$ 0,6923
(-41,82%)
5,96M
EDBLEdible Garden AG Inc
US$ 0,24
(65,06%)
354,33M
NVDANVIDIA Corporation
US$ 134,70
(3,08%)
310,19M
APTOAptose Biosciences Inc
US$ 0,28
(64,51%)
306,25M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,606999
(6,49%)
293,22M
PLTRPalantir Technologies Inc
US$ 80,55
(8,54%)
281,23M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
LUCD
Lucid Diagnostics
LSE
COS
Collagen Solutions
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés